Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Royalty PharmaRPRX 75 Intrinsic Value: Projected FCF is $51.99 as of Sep. 17, 2026. GuruFocus rates RPRX with a GF Score™ of 75/100 and a GF Value™ of $42.93 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 257 Biotechnology companies, Royalty Pharma ranks better than 77.04% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-17), Royalty Pharma's Intrinsic Value: Projected FCF is $51.99. The stock price of Royalty Pharma is $58.47. Therefore, Royalty Pharma's Price-to-Intrinsic-Value-Projected-FCF of today is 1.1.
The historical rank and industry rank for Royalty Pharma's Intrinsic Value: Projected FCF or its related term are showing as below:
RPRX'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.6 Med: 0.78 Max: 1.15
Current: 1.12
During the past 9 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Royalty Pharma was 1.15. The lowest was 0.60. And the median was 0.78.
RPRX's Price-to-Projected-FCF is ranked better than 77.04% of 257
companies
in the Biotechnology industry
Industry Median: 2.09
vs RPRX: 1.12
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Royalty Pharma's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
58.47
/
50.804160963312
=
1.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma Intrinsic Value: Projected FCF Related Terms
Royalty Pharma Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPRX vs INSM, BNTX, INCY: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, Royalty Pharma's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $51.99 mean?
Royalty Pharma (RPRX) has a Intrinsic Value: Projected FCF of $51.99 as of Sep. 17, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #59 out of 257 companies in the Biotechnology industry, placing it in the top 23%.
Is Royalty Pharma's Intrinsic Value: Projected FCF too high?
Royalty Pharma's current Intrinsic Value: Projected FCF is $51.99. The Biotechnology industry median Intrinsic Value: Projected FCF is 2.09. Royalty Pharma's value of $51.99 is 2387.6% above this industry median. Based on the distribution chart, Royalty Pharma ranks #59 out of 257 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Intrinsic Value: Projected FCF compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #59 out of 257 companies for Intrinsic Value: Projected FCF. This places Royalty Pharma in the top 23% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 2.09. Royalty Pharma's value of $51.99 is 2387.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 2.09, based on 257 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Royalty Pharma's current Intrinsic Value: Projected FCF of $51.99 is 2387.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Intrinsic Value: Projected FCF is $51.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (RPRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $42.93, compared to a current price of $58.47 — trading 36.2% above its estimated fair value. The current Intrinsic Value: Projected FCF is $51.99 and 2387.6% above the Biotechnology industry median of 2.09. Royalty Pharma's overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Royalty Pharma (RPRX), the current Intrinsic Value: Projected FCF is $51.99 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (RPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of $58.47 is trading 36.2% above its estimated GF Value™ of $42.93.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for RPRX:
Intrinsic Value: Projected FCF: $51.99
GF Value™: $42.93 vs. price of $58.47 (36.2% above fair value)
Industry Position: 2387.6% above the Biotechnology median (#59 of 257)
No single metric tells the full story. See the RPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
75GF Score
Get the complete analysis for RPRX
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPRX has been successfully added to your 
